Trade name Eloctate.
A recombinant DNA derived, anti-hemophiliac factor indicated in adults and children with hemophilia A for: Control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Mean terminal half-life after a sinle 50 IU/kg in adults.
Regimen ranges of 25-65 IU/kg at 3-5 day intervals.
Higher doses of up to 80 IU/kg may be needed in children <6 years of age.
One- stage clotting assay or chromogenic assay used to monitor plasma factor VIII levels.
With prophylactic 0 bleeds occur in 45% of patients.
Use not associated with inhibitors, or anaphylaxis.
Low incidence of adverse reactions, with about 1% arthralgias and malaise with 0.6% abdominal pain, bradycardia, chest pain, cough, dizziness, myalgias, joint swelling, hypertension, and rash.
Not indicated for the treatment of von Willebrand’s disease.